Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Hereditary Sensory and Autonomic Neuropathies 2Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Advanced BRAF-mutant Cancers 1

Interventions

pembrolizumab 47Cisplatin 24Cetuximab 23Paclitaxel 18Nivolumab 18Radiotherapy 15Docetaxel 15Carboplatin 14Fluorouracil 11tremelimumab 7durvalumab 7Erlotinib Hydrochloride 6avelumab 5Radiotherapy, Intensity-Modulated 5Radiosurgery 5Pemetrexed 4Ipilimumab 4Immunoglobulin G 4Gemcitabine 4Fulvestrant 4Capecitabine 4Bevacizumab 4epacadostat 3cemiplimab 3atezolizumab 3Taxes 3Radiation 3Everolimus 3Cyclophosphamide 3Amifostine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Squamous Cell Carcinoma of Head and Neck × PX-866 × Clear all
NCT01204099 2018-05-16

Study of PX-866 and Docetaxel in Solid Tumors

Seagen Inc.

Phase 1/2 Completed
223 enrolled
Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡